Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

References

• International Diabetes Federation (IDF). IDF Diabetes Atlas – 9th Edition. 2019; [cited 2020 Dec 12]. Available from: https://diabetesatlas.org/en/.
   Google Scholar
• International Diabetes Federation (IDF). About Diabetes. 2019; [cited 2020 Jan 15]. Available from: https://idf.org/52-about-diabetes.html.
   Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
   PubMed Web of Science ®Google Scholar
• Ringborg A, Martinell M, Stålhammar J, et al. Resource use and costs of type 2 diabetes in Sweden – estimates from population-based register data. Int J Clin Pract. 2008;62(5):708–716.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21(9):1477–1483.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6(3):197–202.
   PubMedGoogle Scholar
• Polonsky WH, Fisher L, Hessler D. The impact of non-severe hypoglycemia on quality of life in patients with type 2 diabetes. J Diabetes Complicat. 2018;32(4):373–378.
   PubMed Web of Science ®Google Scholar
• Marrett E, Stargardt T, Mavros P, et al. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009;11(12):1138–1144.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534.
   PubMed Web of Science ®Google Scholar
• O’Reilly DJ, Burke N, Tarride JE, et al. Direct health-care costs and productivity costs associated with hypoglycemia in adults with type 1 and type 2 diabetes mellitus that participated in the Canadian hypoglycemia assessment tool program. Can J Diabetes. 2018;42(6):659–663.
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665–671.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2270.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Tresiba (insulin degludec). 2015; [cited 2020 Jan 16]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba.
   Google Scholar
• Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318(1):33–44.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45–56.
   PubMed Web of Science ®Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723–732.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Feher M, Hansen TK, et al. Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study. J Clin Endocrinol Metab. 2019;104(12):5977–5990.
   PubMed Web of Science ®Google Scholar
• Ericsson Å, Pollock RF, Hunt B, et al. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013;16(12):1442–1452.
   PubMedGoogle Scholar
• York Health Economics Consortium. Dominance [online]. York; York Health Economics Consortium; 2016; [cited 2020 Jan 14]. Available from: https://yhec.co.uk/glossary/dominance/.
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340–349.
   PubMed Web of Science ®Google Scholar
• Lauridsen JT, Lønborg J, Gundgaard J, et al. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res. 2014;23(9):2645–2650.
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(sup1):S5–S26.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(1):S27–S40.
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27(9):2262–2265.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global Health Observatory data repository: Life tables by country (Sweden). 2018; [cited 2020 Dec 09]. Available from: http://apps.who.int/gho/data/view.main.61780?lang=en.
   Google Scholar
• Peasgood T, Brennan A, Mansell P, et al. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type i diabetes. Med Decis Making. 2016;36(8):1020–1033.
   PubMed Web of Science ®Google Scholar
• Li B, Cairns JA, Draper H, et al. Estimating health-state utility values in kidney transplant recipients and waiting-list patients using the EQ-5D-5L. Value Health. 2017;20(7):976–984.
   PubMed Web of Science ®Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25(12):2238–2243.
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–230.
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004;19(6):1594–1599.
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. 1995;311(7020):1595–1599.
   PubMedGoogle Scholar
• Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53(2):677–684.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005;22(11):1482–1486.
   PubMed Web of Science ®Google Scholar
• John WG, Mosca A, Weykamp C, et al. HbA1c standardisation: history, science and politics. Clin Biochem Rev. 2007;28(4):163–168.
   PubMedGoogle Scholar
• Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16(12):1453–1461.
   PubMedGoogle Scholar
• Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006;9(3):193–198.
   PubMed Web of Science ®Google Scholar
• Sørensen J, Plough UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Economics Research International. 2013;2013:1–8.
   Google Scholar
• Statistics Sweden. Average monthly salary by sector 1992–2018. 2019; [cited 2020 Dec 12]. Available from: https://www.scb.se/en/finding-statistics/statistics-by-subject-area/labour-market/wages-salaries-and-labour-costs/salary-structures-whole-economy/pong/tables-and-graphs/average-monthly-salary-by-sector/.
   Google Scholar
• Gerdtham UG, Clarke P, Hayes A, et al. Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics. 2009;27(1):81–90.
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Carlsson K, Kostnader för insjuknande i stroke år 2009. En incidensbaserad studie. [Costs for stroke incidence in 2009. An incidence-based study]. Institutet för hälsooch sjukvårdsekonomi (IHE), Lund Universitet, Sverige [Institute of Health and Medical Economics (IHE), Lund University, Sweden]. 2012: 2.
   Google Scholar
• Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia. 2008;51(10):1826–1834.
   PubMed Web of Science ®Google Scholar
• Palmer A, Goodall G, Nielsen S, et al. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin. 2008;24(5):1417–1428.
   PubMed Web of Science ®Google Scholar
• Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ. 2010;11(2):195–203.
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. CPI, Indices for Main Groups, annual averages. 2019; [cited 2020 Dec 12]. Available from: https://www.scb.se/en/finding-statistics/statistics-by-subject-area/prices-and-consumption/consumer-price-index/consumer-price-index-cpi/pong/tables-and-graphs/consumer-price-index-cpi/cpi-indices-for-main-groups-annual-averages/.
   Google Scholar
• Elliott L, Fidler C, Ditchfield A, et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45–60.
   PubMed Web of Science ®Google Scholar
• Haldrup S, Lapolla A, Gundgaard J, et al. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. J Med Econ. 2020;23(3):271–279.
   PubMedGoogle Scholar
• Evans M, Mehta R, Gundgaard J, et al. Cost-effectiveness of insulin degludec vs. insulin glargine u100 in type 1 and type 2 diabetes mellitus in a UK setting. Diabetes Ther. 2018;9(5):1919–1930.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Valentine WJ, Marso SP, et al. Long-term cost-effectiveness of insulin degludec versus insulin glargine U100 in the UK: evidence from the basal-bolus subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy. 2019;17(5):615–627.
   PubMed Web of Science ®Google Scholar
• Mezquita-Raya P, Darbà J, Ascanio M, et al. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus – from the Spanish National Health System perspective. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):587–595.
   PubMed Web of Science ®Google Scholar